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Abstract
Background: Peripheral arterial disease (PAD) has a population prevalence of 4.6% with intermittent claudication
(IC) presenting as one of the earliest and most common symptoms. PAD has detrimental effects on patients’
walking ability in terms of maximum walking distance (MWD) and pain-free walking distance (PFWD). Research has
suggested extracorporeal shockwave therapy (ESWT) may induce angiogenesis in treated tissue; therefore, our
objective is to assess the tolerability and efficacy of ESWT as a novel treatment of intermittent claudication.
Methods/design: Patients with unilateral claudication will be randomised to receive either ESWT (PiezoWave 2
shockwave system) or sham treatment to the calf muscle bulk three times per week for 3 weeks. All patients are
blinded to treatment group, and all assessments will be performed by a masked assessor. Treatment tolerability
using a visual analogue scale, ankle-brachial pressure index, MWD, PFWD and safety will all be formally assessed as
outcome measures at baseline and at 4, 8 and 12 weeks follow-up.
Discussion: This trial will be the first of its kind in terms of methodology in relation to ESWT for intermittent
claudication. A double-masked randomised controlled trial will provide useful information about the potential for
the use of ESWT as a non-invasive treatment option and the need for further robust research.
Trial registration: ClinicalTrials.gov, NCT02652078. Registered on 17 October 2014.
Introduction
Peripheral arterial disease (PAD) is common in western
society with a prevalence estimated at 20% of those aged
over 60 [1]. Intermittent claudication (IC), a manifestation
of PAD in the lower limbs, causes sufferers to experience
cramping pain in the affected muscles, most commonly
the calves, which occurs after walking a short distance and
increases in intensity until the person stops, where the
pain then gradually subsides. PAD can be limiting or occa-
sionally debilitating and has been shown to have consider-
able deleterious effects on patients’ quality of life [2].
There is a 15-fold increase in mortality secondary to
cardiovascular disease in symptomatic patients with severe
large vessel PAD; therefore, treatment is based around
minimising cardiovascular risk factors and reducing risk
of disease progression [3]. With conservative management
strategies a proportion of patients will remain with stable
symptoms, whilst a minority will deteriorate and require
intervention in the form of an endovascular or open
vascular surgical procedure.
The physiological negative effects caused by PAD are
hypothesised to be due in part to recurrent episodes of
ischaemia-reperfusion injury (IRI), which occurs as
claudicants exercise (ischaemia) and rest (reperfusion).
IRI causes progression of atherosclerosis, as well as endo-
thelial dysfunction and end organ damage [4–6]. During
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ischaemic episodes and subsequent reperfusion, leuco-
cytes become activated, resulting in release of proteolytic
enzymes, cytokines and reactive oxygen species [7, 8].
Background
A shockwave is described as a transient short-term acous-
tic pulse with a high peak pressure. This waveform gener-
ation and rise to peak pressure occur within nanoseconds
[9]. Biological effects of shockwaves on human tissue were
first documented during World War II when severe lung
injuries secondary to water bombs were noted within
casualties who did not display any evidence of external
injury [10]. The medicinal use of high energy extracorpor-
eal shockwaves did not develop until the 1980s, when they
were targeted to fragment urinary stones (lithotripsy);
results led to this technique becoming the gold standard
treatment option for urolithiasis [9]. From this point the
developing use of extracorporeal shockwave therapy
(ESWT) followed an interesting course which started after
an incidental finding of iliac bone thickening in patients
undergoing lithotripsy, which proposed the potential
osteoblastic effect of shockwave therapy [11]. Researchers
confirmed these observations through a number of clinical
trials using shockwave therapy on delayed non-union frac-
tures [12–14]. Observational improvements to soft tissue
wounds overlying these fractures treated with ESWT then
encouraged research into the benefits of shockwave ther-
apy in hard-to-heal chronic soft tissue wounds [15].
The exact mechanism of action of ESWT on soft tissue
is not fully understood, although the principle of mechan-
otransduction is thought to be responsible for the bio-
logical changes that take place. Mechanotransduction is
the transfer of mechanical stimuli into chemical signals;
this takes place at a cellular level where mechanosensory
components within the cell wall are stimulated, which
activates gene expression of growth factors and cytokines
as well as cell proliferation or differentiation [16]. The
mechanical force is a secondary effect of cavitation which
can be visualised in water by the creation of cavitation
bubbles that then emit secondary shockwaves. This phys-
ical force can also be seen when shockwaves are directed
over a thin aluminium foil, which show the effect of cavi-
tation bubbles collapsing on or near the foil [17].
Increased expression of growth factors such as endothe-
lial nitric oxide synthase (eNOS) and vascular endothelial
growth factors (VEGFs) have been demonstrated following
treatment of soft tissues with ESWT during various stud-
ies both in vivo and in vitro. However, the majority of this
evidence is from animal studies, and further investigation
is required [18–21].
Due to these findings, further applications of ESWT are
beginning to be explored. One such application included
the use of ESWT to treat ischaemic heart disease where
focussed shockwaves were directed at ischaemic areas of
myocardium. This demonstrated some positive findings
with notable results including improvement in left
ventricular ejection fraction (LVEF), ventricular wall
thickening, reduced symptoms, reduced nitroglycerine use
and again increased upregulation of growth factors and
angiogenesis [22]. A further use has potentially been
found with small trials commencing in ESWT for periph-
eral vascular disease, which has led to the development of
this current protocol.
Summary of current evidence
To date, four studies have investigated ESWT in claudi-
cants (Table 1). They include one randomised control trial
of 22 patients with 12 patients receiving treatment and 10
receiving a sham control. This study targeted ESWT at a
stenotic plaque lesion within lower limb arteries and
demonstrated significant reduction in degree of arterial
stenosis, significant improvement in pain-free walking
distance (PFWD) and reduction in pain severity. These
findings were also coupled with a significant reduction in
Fontaine staging [23].
Another study was a small prospective non-randomised
pilot study of 10 patients which aimed to prove safety; its
primary end point was observation of adverse events. This
study found no adverse events secondary to shockwave
therapy. The secondary end point was a measure of tissue
perfusion using scintography, laser Doppler and measure-
ment of transcutaneous oxygen tension (TcPO2). The use
of scintography demonstrated significantly improved
tissue perfusion in the dorsum of the foot; however, perfu-
sion was unchanged in the lower leg region. Maximum
TcPO2 increased significantly in both the calf region and
dorsum of the foot. Skin perfusion pressure measured
using the laser Doppler showed increases in both regions,
but neither was significant [24].
Another prospective study of 32 patients underwent
EWST for critical limb ischaemia with both rest pain
and localised distal necrosis. Outcomes included PFWD,
visual analogue scale (VAS) for pain, laser Doppler skin
perfusion, partial pressure of oxygen and partial pressure
of carbon dioxide. All of these outcomes demonstrated
significantly improved measurements [25].
Finally a further two prospective non-randomised trials
by Serizawa et al. with a total of 6 patients and then 12 pa-
tients with Fontaine stage II PAD were treated with ESWT
and demonstrated significantly improved maximum walk-
ing distance, shorter recovery time and improved walking
impairment questionnaire scores [26].
Aims and objectives
This study aims to compare the effects of extracorporeal
shockwave therapy (ESWT) to the use of a sham control
group on walking distances in subjects with lower limb
intermittent calf claudication.
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Primary outcome
The primary outcome is the effect of extracorporeal
shockwave therapy in comparison to sham treatment on
the maximum walking distance (MWD) — the distance
covered before the subject is unable to continue — at
baseline and at 4 weeks, 8 weeks and 12 weeks post
therapy.
Secondary outcomes
The secondary outcomes are as follows:
 Claudication distance, i.e. distance covered prior to
onset of any symptoms, at baseline and at 4 weeks,
8 weeks and 12 weeks post therapy
 Ankle-brachial pressure index (ABPI), measured at
baseline and at 4 weeks, 8 weeks and 12 weeks post
therapy
 Patient reported walking distance at baseline,
4 weeks, 8 weeks and 12 weeks post therapy
 Quality of life as measured by Short Form 36
questionnaire (SF-36) at baseline, 4 weeks, 8 weeks
and 12 weeks post therapy
 Quality of life as measured by the EuroQol 5
domains questionnaire (EQ-5D) at baseline, 4 weeks,
8 weeks and 12 weeks post therapy
 Subject tolerance of treatment, measured by VAS
after each individual treatment session
Design
This is a single-centre, double-blinded randomised con-
trolled trial comparing extracorporeal shockwave ther-
apy (ESWT) to sham treatment in the management of
intermittent calf claudication.
Setting
The trial will be conducted in the Academic Vascular
Surgical Unit of the Hull York Medical School, based at
Hull Royal Infirmary (University Teaching Hospital). All
procedures will be performed in an outpatient-based or
day-case setting.
Patient identification
Patients will be recruited from vascular outpatient
clinics and assessed for inclusion by the research team
against the listed inclusion and exclusion criteria. In
order to achieve target sample size, all patients identified
as suffering from PAD will be screened for inclusion.
Target population and recruitment
Inclusion criteria
Patients will be included who:
 Have unilateral or bilateral intermittent calf
claudication (stable for the last 3 months)
 Are able to give written informed consent to
participate in the study
Table 1 Human studies related to ESWT for peripheral arterial disease
Study/author(s) Type Sample size Methods Significant results Limitations
Ciccone MM,
Notarnicola A [23]
Randomised
control trial
N = 22,
cases = 12,
controls =10
4 sessions at 1 weekly intervals,
2000 impulses, 0.03 mJ/mm2.
Aimed at stenotic lesion
Increased pain-free walking distance
and reduction in pain severity.
Reduction in degree of arterial
stenosis. Reduced Fontaine staging
Small sample size,
short-term follow-up
Tara S,
Miyamoto M [24]
Prospective
non-randomised
pilot study
N = 10 6 sessions (3 times per week
for 2 weeks).
6 spots per session (300 impulses/
spot) 0.11–0.12 cmJ/mm2
No adverse events.
Improved transcutaneous oxygen
tension (TcPO2) in both calf and
dorsum of foot. Scintography
demonstrated improved perfusion
in dorsum of foot only
Small sample size,
non-randomised,
short-term follow-up
Belcaro G,
Cesarone MR [25]
Prospective
non- randomised
N = 32 6 sessions (3 times per week
for 2 weeks) 1000 impulses
per session, 0.08–0.43 mJ/mm2
Improved pain-free walking
distance, analogue scale for pain,
laser Doppler skin perfusion, partial
pressure of oxygen and decreased
partial pressure of carbon dioxide.
Reduced ORACLE score
Small sample size,
non-randomised
short-term follow-up
Serizawa F,
Ito K [26]
Prospective
non-randomised
N = 12 9 sessions (3 times per week
for 3 weeks) 40 spots per session
with 200 impulses/spot 0.1 mJ/mm2
Improved maximum walking
distance, walking impairment
questionnaire scores and
shorter recovery time
Small sample size,
non-randomised,
short-term follow-up
Serizawa F,
Ito K [26]
Prospective
non-randomised
N = 6 6 sessions (3 times in first week
(days 1, 3 and 5) and 3 sessions
in week 5 (days 29, 31, 33) 40
spots per session with 200
impulses/spot 0.1 mJ/mm2
The maximum walking distance
was significantly increased at
4 weeks and 8 weeks follow-up
Small sample size,
non-randomised,
short-term follow-up
Data captured in italic are significant outcome for measures in the trial protocol
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 Are >18 years old
 Are able to adhere to the protocol and attend all
follow-up appointments
 Are currently receiving ’best medical therapy’ —
antiplatelet and statin medication
Exclusion criteria
Patients will be excluded if they:
 Currently have a malignancy
 Are allergic to or intolerant of either antiplatelet
medication or statin therapy
 Are pregnant (pregnancy test performed at
screening if necessary)
 Have a metal implant near the treatment area
 Are taking anticoagulation medication (i.e. warfarin)
 Are diagnosed with a blood clotting disorder
Screening and evaluation
Patients identified as potential participants will undergo
a screening interview.
Baseline data will be collected from all consenting par-
ticipants. Data collected will include:
 Evaluation of compliance with inclusion and
exclusion criteria
– Issue of Patient Information Sheet if not already
issued
 Informed consent (24 hours later)
 Participant’s name and address and, if used by the
participant, mobile telephone number and email
address (for the receipt of follow-up questionnaires)
and date of birth
 Details on participant’s general practitioner
 Demography and medical history
 Physical examination to include palpation of lower
limb pulses
 Ankle-brachial pressure index (ABPI)
 Vital signs
 Assessment of any concurrent medications
 Pregnancy test if necessary
 Body mass index (BMI)
 Smoking history
 Baseline quality of life
Appropriately screened and consented individuals will
be further assessed as follows:
1. Baseline visit
(a)Patient reported walking distance (PRD)
(b)Vital signs
(c)Quality of life
(d)Treadmill assessment to report intermittent
claudication distance (ICD) and maximum
walking distance (MWD)
For treadmill walking distances, ICD and MWD
will be measured on a treadmill at 2.5 km/h at a
10° incline for up to 10 minutes. Participants will
be asked to rest for 30 minutes prior to testing to
ensure a resting state and negate effects of
mobilising to the vascular laboratory.
Randomisation will occur at the end of the
baseline visit via sealed envelope software to
either active treatment or control group by a
second investigator. The treatment will then
proceed as follows:
(e)The second investigator will then perform
ESWT therapy for the active group and sham
treatment for the control group. Sham
treatment will be delivered by setting the
generator to off and replicating the sound of
the active treatment via an audio recording
emitted from the machine
(f ) All patients will then complete a tolerability
questionnaire for the ESWT treatment.
2. Weeks 1, 2, 3 visits
(a)Vital signs
(b)ESWT performed by second investigator with
pulsewave generator on for active group and off
for control group
(c)Patient to complete tolerability questionnaire for
ESWT treatment
(d)PRD recorded
(e)Assessment of any concurrent medications
(f )Assessment of any adverse events
3. Week 4, 8, 12 visits
(a)PRD
(b)Vital signs
(c)Quality of life
(d)Treadmill assessment to report ICD and MWD
(e)Assessment of any concurrent medications
(f )Assessment of any adverse events
Method/design
Trial treatments/study procedures
Patients on the treatment arm of the trial will receive
ESWT using the PiezoWave2 shockwave system, in
accordance with the manufacturer’s instructions and un-
changed from its current clinical use at 100 impulses
0.1 mJ/mm per cm2. Trained staff will provide all treat-
ments, including sham treatment. Both local research
and development and medical physics departments
deem this device low risk and safe to use. The device
will be targeted at the gastrocnemius muscles of the af-
fected lower leg for several minutes at each treatment
session. Participants in the control group will undergo
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an identical process as if treatment were being given but
with the shockwaves not being administered and the
sham treatment described above alternatively used.
1 shockwave session = 100 impulses per cm2 covering
two areas per affected leg, with one (6 cm × 5 cm) on
the medial head of the gastrocnemius and one (6 cm ×
5 cm) on the lateral head of the gastrocnemius. This cal-
culates as 6000 impulses/5 Hz/0.1 mJ/mm2 in total.
Environmental conditions
A designated clinical room in the vascular laboratory at Hull
Royal Infirmary will be used for all examination and treat-
ments. The device will be applied to the gastrocnemius
muscle of the affected limb/s at two sites (medially and lat-
erally). One course of treatment will consist of three separate
treatment sessions per week on alternate days for 3 weeks.
Outcome measurements
Primary outcome
The primary outcome is the short-to-medium term ef-
fect of ESWT in comparison to sham treatment on
MWD in patients suffering intermittent calf claudication
at baseline, 4 weeks, 8 weeks and 12 weeks post therapy.
Secondary outcomes
The secondary outcomes are as follows:
 Claudication distance (CD) — the distance covered
prior to onset of any symptoms — at baseline,
4 weeks, 8 weeks and 12 weeks post therapy
 Pre and post treatment ABPI at baseline, 4 weeks,
8 weeks and 12 weeks post therapy
 Patient reported walking distance (PRD) at baseline,
4 weeks, 8 weeks and 12 weeks post therapy
 Acceptability and tolerability of the treatment measured
by VAS after each individual treatment session
– Control group patients will be asked to complete
tolerability questionnaires as if they were
receiving active treatment.
 Quality of life as measured by SF-36 at baseline,
4 weeks, 8 weeks and 12 weeks post therapy
 Quality of life as measured by the EQ-5D at baseline,
4 weeks, 8 weeks and 12 weeks post therapy
Assessments
Following completion of the consent procedure, baseline
data will be collected as defined above. Outcome measure-
ments will then be recorded according to the subsequent
study visits. See Fig. 1 and Table 4.
Assessments prior to the first ESWT therapeutic session
Assessments prior to the first EWST session are:
 PRD
 ABPI
 Claudication distance
 Maximum walking distance
 Quality of life questionnaires (SF-36 and EQ-5D)
Assessments during all therapeutic treatments
During all therapeutic treatments, we will assess:
 Pain rating of treatment using VAS
 Quality of life questionnaires (SF-36 and EQ-5D)
Assessments during weeks 4, 8 and 12 follow-up
appointments
Assessments at weeks 4, 8 and 12 are:
 Tolerability questionnaire (week 4 only)
 PRD
 ABPI
 Claudication distance
 Maximum walking distance
 Quality of life questionnaires (SF-36 and EQ-5D)
Concurrent medications
The study will not influence clinical management of the
patient; therefore, there are no restrictions of prescribed
medication. Researchers will monitor concomitant medi-
cations taken by the patients at screening and during the
entire study period.
Adverse events
Serious adverse events will be reported to the Sponsor
and the National Research Ethics Service (NRES) recog-
nised Research Ethics Committee (REC).
The device
The device being used in this trial is the PiezoWave 2.
Training and support are provided by Impact Medical,
Liverpool, UK.
Safety and tolerability
The device is a CE-marked (CE 93/42/EEC) British
Standards Institute, notified body 0086), commercially
available device. Trained staff will manage the device
and are responsible for applications of treatment. The
facilities where participants will be assessed are fully
equipped for all emergency situations.
Safety reporting
The safety definitions are given below.
Adverse event (AE): An AE is any untoward medical
occurrence in a subject to whom a medicinal product
has been administered as part of a research study, in-
cluding occurrences which are not necessarily caused by
or related to an investigational medicinal product (IMP).
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Adverse reaction (AR): An AR is any untoward and
unintended response in a subject to an IMP which is
related to any dose administered to that subject.
Important medical events that may not be immediately
life-threatening or result in death or hospitalisation but
may jeopardise the patient or may require intervention
to prevent one of the other outcomes listed in the defin-
ition above should also be considered serious.
Serious adverse event (SAE): An SAE is an event not
related or unlikely to be related to the IMP. An adverse
event becomes serious if it:
 Results in death
 Is life-threatening
 Requires hospitalisation or prolongation of existing
hospitalisation
 Results in persistent or significant disability or
incapacity
 Is a congenital anomaly or birth defect
Serious adverse reaction (SAR): A SAR is a serious
event which is suspected (possibly, probably or defin-
itely) to be related to an IMP and expected for the IMP.
Suspected unexpected serious adverse reaction (SUSAR):
A SUSAR is a serious event which is suspected (possibly,
probably or definitely) to be related to an IMP and
unexpected for the IMP, i.e. not previously documented in
any of the IMP information (investigator brochure, Sum-
mary of Product Characteristics, patient information leaf-
let) or protocol on device deficiencies.
Device deficiency: A device deficiency is an inadequacy
of a medical device with respect to its identity, quality,
durability, reliability, safety or performance. All device
deficiencies will be recorded and reported accordingly.
Anticipated and unanticipated serious adverse device
effects (SADE/USADE): There are no known SADEs with
this device; therefore, all SADEs are, by definition,
unanticipated.
If a USADE is suspected, no additional patients will be
enrolled until the cause of the event and its relationship
to the study device have been determined. If the event is
device-related, the following action will be necessary. If
there is a specific type of patient who is vulnerable to
the event, then the inclusion/exclusion criteria will be
amended to exclude this ’at risk’ group.
The protocol procedures may be revised including but
not limited to the duration of therapy. The study may
also be stopped. See Table 2.
Causality and adverse device effects
The relationship of both AEs and SAEs to the study
device will be determined as follows (Table 3).
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram
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The Investigator must endeavour to obtain sufficient in-
formation to determine the causality of the AE and must
provide his/her opinion of the causal relationship between
each AE and the study device. This may require instituting
supplementary investigations of significant AEs based on
their clinical judgement of the likely causative factors and/
or include seeking a further opinion from a specialist in
the field of the AE.
Adverse event and device deficiency reporting
All AEs during the study will be reported on the Adverse
Event page of the Case Report Form (CRF). If events are
deemed serious, a separate Serious Adverse Event form
will also be completed.
Device deficiencies during the study will be recorded on
a dedicated form. The Principal Investigator will record the
action taken to alleviate the AE/SAE. AEs may be recorded
as ongoing at the end of the study, but SAEs will be
followed up until resolved. Trained medical personnel will
be accessed to act with appropriate diagnostic and thera-
peutic measures until the subject has recovered. SAEs will
be reported to the Principal Investigator within 24 hours.
Withdrawals and dropouts
During the study, treatment may be discontinued for
many reasons such as the occurrence of a disease, an AE
that could interfere with the subject’s evaluation or simply
upon the subject’s request to discontinue for any reason.
Concurrent medical events that do not interfere with
scheduled testing and that are judged by the Investigator
to not have an effect on the outcome measures will not
disqualify a subject from continuing in the study. If a
subject is withdrawn from the study because of an AE,
treatment discontinuation must be explained on the
Adverse Event page of the CRF.
Patients will be advised that they are free to withdraw
from the study at any time for any reason or, if neces-
sary, the Investigator may withdraw a subject from the
study to protect the subject’s health. The Investigator
may withdraw a subject from the study if it is considered
that the scientific, and therefore, ethical standards of the
study are compromised. Patients may also be withdrawn
for not complying with study procedures. The type and
timing of the withdrawal for withdrawal will be fully
recorded on the CRF. Should a patient choose to with-
draw from treatment, they will be asked if they are still
available for follow-up data collection.
Trial exit
Participants will exit the trial completely if:
 They have completed their participation
 They request to/are unable to continue being
followed up
 They experience an AE (if the AE is deemed due to
trial involvement) such that they are unable to
complete follow-up
 They die
Overall timescale for the study
Recruitment began as soon as all necessary approvals
(REC, Medicines and Healthcare products Regulatory
Agency (MHRA) and Trust R&D) were obtained. The
intention is that recruitment will run until a power calcu-
lation of participant number is reached. A power calcula-
tion will be performed from ongoing cohort study and
existing evidence with a maximum of 100 participants in
total. Patients are involved in the trial for 12 weeks only.
The outline of events is given in Table 4.
Study completion
Completion refers to the date of final data collection
from the last patient. Paper records from the trial will be
stored for 5 years from trial end.
Data will be collected and collated using a specifically
designed database which will be kept on hospital central
servers on a limited access hard drive. Access will be via
password-protected log-in on hospital servers only and
will be limited to members of the Academic Vascular
Surgery Unit. The file itself will have password-protected
Table 2 Summary of adverse events
Adverse
events
Non-device-
related
Device-related
Non-serious Adverse
event (AE)
Adverse device effect (ADE)
Serious Serious adverse device effect (SADE)
Anticipated Unanticipated
Anticipated serious
adverse device
effect (ASADE)
Unanticipated serious
adverse effect
(USADE)
Table 3 Causality of adverse events
Causality Definition
Almost certainly Starts within a time related to the operation
of the device, and
No obvious alternative medical explanation
Probably Starts within a time related to the operation
of the device, and
Cannot be reasonably explained by known
characteristics of the patient’s clinical state
Possibly Starts within a time related to the operation
of the device, and
A causal relationship between the operation
of the device and the adverse event is at
least a reasonable possibility
Unrelated The AE is definitely not associated with the
study device
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opening. Electronic records will be stored for 5 years
from trial end.
Data management
The use and control of all data will comply at all times
with the requirements of the Data Protection Act 1998.
The Principal Investigator of the study will register with
the local Data Protection Officer. All data management
procedures will be detailed and referred to as the Data
Management Plan. All data will be entered and checked
by a second person.
The database will be designed and built by the re-
search team using Microsoft Excel. Appropriate CRFs
will be prepared for the collection of the data requested
by the protocol. All response variables will be entered
into the database by the data management personnel.
Statistical considerations
Statistical advice has been sought from the Statistical
Consultancy Service (Hull York Medical School, Univer-
sity of York) in preparing this protocol. Further review
will be sought when all results have been collected and
the analysis performed.
Data will be analysed as intention to treat. The SPSS
computer package will be used with a p value of <0.05
taken as the level of significance.
Sample size calculation
A power calculation will be performed from the ongoing
cohort study and existing evidence with a maximum of
100 participants in total.
Analysis
Data will be analysed on an intention-to-treat basis. The
main aim is to provide estimates of distribution and vari-
ability of outcomes with comparisons made between the
shockwave treatment group and sham group. These will
be expressed principally as means or medians and confi-
dence intervals.
Monitoring and quality assurance
The Principal Investigator is responsible for the day-to-
day monitoring and management of the study. The
Research Office, on behalf of the Sponsor, will monitor
and conduct random audits on a selection of studies in
its clinical research portfolio. Monitoring and auditing
will be conducted in accordance with the Department of
Table 4 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram of events timeline
Study period
Enrolment and
screening
Allocation Post randomisation Exit
Timepoint Treatment period 4/52 F/U 8/52
F/U
12/52
F/U
Enrolment:
Eligibility screen X
Demographics X
Past medical history X
Provision of Patient Information Sheet X
Informed consent X
Randomisation/allocation X
Interventions:
Active shockwave treatment (Group A) 9 sessions
(3 × per week for 3 weeks)
Sham treatment (Group B) 9 sessions
(3 × per week for 3 weeks)
Assessments:
Ankle-brachial pressure index X X X X
Claudication distance X X X X
Maximum walking distance X X X X
SF-36 questionnaire X X X X
EQ-5D questionnaire X X X X
Patient tolerability VAS Recorded after each treatment
Adverse events (bruising, bleeding, etc.) Recorded after each treatment X X X
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Health Research Governance Framework for Health and
Social Care (April 2005), and in accordance with the
Sponsor’s monitoring and audit policies and procedures.
The organisation, monitoring and quality assurance of
this clinical study are the responsibility of the Sponsor
and the Principal Investigator. To ensure the accuracy of
data, direct access to source documents by the represen-
tatives of both the Sponsor and regulatory authorities is
mandatory. Anonymity of the subjects will be main-
tained at all times.
The investigator(s)/institution(s) will permit study-
related monitoring, audits, REC review and regulatory
inspection(s), providing direct access to source data/doc-
uments. Patient consent to this is specifically sought in
the Informed Consent Form.
Study completion or discontinuation
Upon completion of the study, the following activities,
when applicable, must be conducted by the Investigator
and by the Sponsor’s Monitor, as appropriate:
 Data clarifications and/or resolutions
 Review of site study records for completeness
In addition, the Sponsor, the Funder and the Principal
Investigator reserve the right to temporarily suspend or
prematurely discontinue this study for any reason. If
such action is taken, the Sponsor will discuss this with
the Funder and the Investigator (including the reasons
for taking such action) at that time.
If the study is terminated for safety reasons, the Spon-
sor will promptly inform the regulatory authorities of
the suspension or termination of the study and the rea-
son(s) for the action. The Investigator must inform the
REC promptly and provide the reason for the suspension
or termination. After such a decision, the Investigator
must call in all participating patients within a reasonable
time period. At this visit all medical files and CRFs must
be completed as far as possible.
Administrative procedures
Ethical considerations
This protocol has been prepared in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist. See Additional file 1.
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki (Ethical Principles for
Medical Research Involving Human Subjects).
Participant data protection
Participants will be informed that their data are held on
file and that these data may be viewed by the Sponsor
and by external auditors on behalf of either the Sponsor
or regulatory agencies. Participants will similarly be
informed that these data and a report of the study will
be submitted to the Sponsor and may also be submitted
to government agencies and perhaps for publication, but
that they will only be identified in such reports by their
study identification number, initials and perhaps their
gender and age. The investigators undertake to hold all
personal information in confidence and in compliance
with the Data Protection Act 1998 and Caldicott
Committee policies.
Data will be collected and collated using the database
and data analysis software SPSS. This will be kept on
hospital central servers on a limited access hard drive.
Access will be via password-protected log-in on hospital
servers only and will be limited to members of the
Academic Vascular Surgery Unit. The file itself will have
password-protected opening.
Data handling and record keeping
The Principal Investigator will be responsible for data
collection, recording and quality. Electronic data will be
stored on a National Health Service (NHS) Trust com-
puter within the vascular laboratory. The IT services de-
partment has a backup procedure approved by auditors
for disaster recovery. Servers are backed up to tape
media each night; the tapes run on a 4-week cycle. Files
stay on the server unless deleted by accident or deliber-
ately. Anything deleted more than 4 weeks previously is
therefore lost. Additional archive backups are taken for
archived data, so data should not be lost from this type
of system, e.g. with the use of FileVision, which stores
medical records. Tapes are stored in a fireproof safe.
Study documents (paper and electronic) will be retained
in a secure location and kept locked when not in use
during the trial and after it has finished. All essential
documents including source documents will be retained
for a minimum period of 5 years after study completion
(last visit of the last patient). A label stating the date
after which the documents can be destroyed will be
placed inside the front cover of the case notes of trial
participants. Data will be collected and retained in
accordance with the Data Protection Act 1998.
Indemnity
This is an NHS-sponsored research study. If there is
negligent harm during the clinical trial when the NHS
body owes a duty of care to the person harmed, NHS
indemnity covers NHS staff and medical academic staff
with honorary contract only when the trial has been ap-
proved by the Hull and East Yorkshire R&D department.
NHS indemnity does not offer no-fault compensation
and is unable to agree in advance to pay compensation
for non-negligent harm. The University of Hull has an
insurance policy that includes cover for no-fault compen-
sation in respect of accidental injury to a research subject.
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Discussion
There is significant research suggesting a neovascularisa-
tion/angiogenic response to ESWT when applied to soft
tissue. However, only several small, low-level research
trials have investigated the use of ESWT in patients with
peripheral arterial disease and, more specifically, inter-
mittent claudication. Non-invasive management of
patients suffering from intermittent claudication consists
of best medical treatment plus supervised exercise
programmes (SEPs). Unfortunately, uptake and adher-
ence to SEPs is extremely poor in most centres; there-
fore, there is potential for an alternative non-invasive
treatment option. The purpose of this study is to firstly
investigate whether this treatment is safe and well toler-
ated by patients when applied to the calf muscle bulk,
and also to study whether the angiogenic response seen
in soft tissue research relating to ESWT has a positive
effect on this cohort of patients and whether it is signifi-
cant enough to improve clinical outcomes such as max-
imum walking distance, pain-free walking distance and
ankle-brachial pressure index.
Trial status
This trial remains in the recruitment phase.
Additional file
Additional file 1: SPIRIT checklist. (DOC 121 kb)
Abbreviations
ABPI: Ankle-brachial pressure index; BMI: Body mass index; BMT: Best medical
treatment; CI: Confidence interval; CILLI: Clinical indicator of lower limb
ischaemia; CLI: Critical limb ischaemia; CRP: C-reactive protein;
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SF-36: Short Form 36; TASC: Trans-Atlantic Inter-Society Consensus;
vLDL: Very low-density lipoprotein; vWF: Von Willebrand factor
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The trial will be reported in accordance with the CONSORT statement
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Before enrolment into the study, participants will be fully informed of the
nature of the study and all relevant aspects of study procedures. It is the
investigators’ responsibility to explain the nature of the study, its purpose
and associated procedures, the expected duration and the potential benefits
and risks of participation to each subject prior to their entry into the study
(i.e. before examinations and procedures associated with selection for the
study are performed).
Each prospective candidate will be provided with the Patient Information
Sheet and Informed Consent Forms, to be compiled as one integrated
document. Each subject will have ample opportunity to ask questions and
will be informed about his/her right to withdraw from the study at any time
without any disadvantage and without having to provide reasons for this
decision.
Once the essential study information has been provided and the Investigator
is assured that each individual patient understands the implications of
participating in the study, the eligible patients who pass the screening
evaluation will be recruited. Informed Consent Forms shall be signed and
dated by the appropriate parties. A notation that written informed consent
has been obtained will be made on the CRF and a record made in their
clinical notes. Completed Informed Consent Forms will be retained by the
Investigator, a copy entered into the clinical notes and a copy provided by
the Investigator to the patient. The Informed Consent Form is included as
part of the submission to the REC.
The Informed Consent Form and any other written information provided to
subjects will be revised whenever important new information becomes
available that may be relevant to the subject’s consent, or there is an
amendment to the protocol which necessitates a change to the content of
the subject information and/or the written Informed Consent Form. The
investigators will inform the subject of changes in a timely manner and will
ask the subject to confirm their continued participation in the study by their
signature on the revised Informed Consent Form. Any revisions to the
written Informed Consent Form and written information will receive main
REC approval in advance of use.
Patients will be free to withdraw at any time without affecting their
healthcare or legal rights.
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Hull and East Yorkshire NHS Trust will act as the study Sponsor, as the study
takes place on an NHS hospital site. They are responsible for the monitoring
of the study. They have had no input into the study design or data
collection.
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